{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:19:51Z","timestamp":1789957191641,"version":"4.0.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014081","name":"Center for Craft, Creativity and Design","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010638","name":"University of Utah Health Huntsman Cancer Institute","doi-asserted-by":"publisher","award":["P30 CS042014"],"award-info":[{"award-number":["P30 CS042014"]}],"id":[{"id":"10.13039\/100010638","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jconrel.2025.113682","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T03:58:20Z","timestamp":1743739100000},"page":"113682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["PD-L1 targeted antibody-polymer-Epirubicin conjugate prolongs survival in a preclinical murine model of advanced ovarian cancer"],"prefix":"10.1016","volume":"382","author":[{"given":"Jiahui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Al Faruque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Sima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Sborov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwen","family":"Hu-Lieskovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jind\u0159ich","family":"Kope\u010dek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.113682_bb0005","article-title":"Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancer","volume":"39","author":"Vanguri","year":"2022","journal-title":"Gynecol. Oncol. Reports"},{"key":"10.1016\/j.jconrel.2025.113682_bb0010","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2025.113682_bb0015","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41571-024-00937-4","article-title":"Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach","volume":"21","author":"Ghisoni","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.113682_bb0020","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2025.113682_bb0025","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.3390\/cancers12082223","article-title":"Antibody-drug conjugates: a promising novel therapy for the treatment of ovarian cancer","volume":"12","author":"Manzano","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2025.113682_bb0030","first-page":"875","article-title":"Antibody-drug conjugates for the treatment of ovarian cancer, expert Opin","volume":"21","author":"Calo","year":"2021","journal-title":"Biol. Ther."},{"key":"10.1016\/j.jconrel.2025.113682_bb0035","doi-asserted-by":"crossref","DOI":"10.1177\/11795549231187264","article-title":"Mirvetuximab soravtansine in platinum-resistant ovarian cancer","volume":"17","author":"Gonzalez-Ochoa","year":"2023","journal-title":"Clin. Med. Insights Oncol."},{"key":"10.1016\/j.jconrel.2025.113682_bb0040","series-title":"Antibody-polymer-drug conjugates, US 11,801,307 B2","author":"Yang","year":"2023"},{"key":"10.1016\/j.jconrel.2025.113682_bb0045","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejps.2017.02.034","article-title":"A new construct of antibody-drug conjugates for treatment of non-Hodgkin\u2019s lymphoma","volume":"103","author":"Zhang","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"issue":"Supp.1","key":"10.1016\/j.jconrel.2025.113682_bb0050","article-title":"Development of next generation antibody-polymer-drug conjugates for treatment of multiple myeloma","volume":"142","author":"Li","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2025.113682_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120827","article-title":"Targeting PD-1\/PD-L1 axis as new horizon for ovarian cancer therapy","volume":"306","author":"Khatoon","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.jconrel.2025.113682_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1328651","article-title":"Targeting the immune microenvironment for ovarian cancer therapy","volume":"14","author":"Blanc-Durand","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2025.113682_bb0065","article-title":"Inhibition of immunosuppresive tumors by polymer-assisted inductions of immunogenic cell death and multivalent PD-L1 crosslinking","volume":"30","author":"Li","year":"2020","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2025.113682_bb0070","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jconrel.2021.02.011","article-title":"Combination treatment with immunogenic and anti-PD-L1 polymer-drug conjugates of advanced tumors in a transgenic MMTV-PyMT mouse model of breast cancer","volume":"332","author":"Li","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113682_bb0075","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrc3432","article-title":"Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research","volume":"13","author":"Kipps","year":"2013","journal-title":"Natl. Rev."},{"key":"10.1016\/j.jconrel.2025.113682_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810692","article-title":"Immune tumor microenvironment in ovarian cancer ascites","volume":"23","author":"Almeida-Nunes","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2025.113682_bb0085","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0014-3057(73)90063-3","article-title":"Poly[N-(2-hydroxypropyl)methacrylamide]. 1. Radical polymerization and copolymerization","volume":"9","author":"Kope\u010dek","year":"1973","journal-title":"Eur. Polym. J."},{"key":"10.1016\/j.jconrel.2025.113682_bb0090","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jconrel.2015.09.045","article-title":"FRET-trackable biodegradable HPMA copolymer-epirubicin conjugates for ovarian carcinoma therapy","volume":"218","author":"Yang","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113682_bb0095","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1021\/ma0018087","article-title":"Water-soluble polymers. 81. Direct synthesis of hydrophilic styrenic-based homopolymers and block copolymers in aqueous solution via RAFT","volume":"34","author":"Mitsukami","year":"2001","journal-title":"Macromolecules"},{"key":"10.1016\/j.jconrel.2025.113682_bb0100","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jconrel.2016.06.004","article-title":"Indium-based and iodine-based labeling of HPMA copolymer-epirubicin conjugates: impact of structure on the in vivo fate","volume":"235","author":"Zhang","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113682_bb0105","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.2015.63.7785","article-title":"Targeting programmed cell death 1 in ovarian cancer","volume":"33","author":"Homicsko","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.113682_bb0110","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.addr.2020.07.020","article-title":"Polymer nanomedicines","volume":"156","author":"Kope\u010dek","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.113682_bb0115","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/(SICI)1097-0215(20000401)86:1<108::AID-IJC17>3.0.CO;2-8","article-title":"Efficacy of chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma","volume":"86","author":"Minko","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2025.113682_bb0120","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cocis.2017.07.003","article-title":"The light at the end of the tunnel \u2013 second generation HPMA conjugates for cancer treatment","volume":"31","author":"Yang","year":"2017","journal-title":"Curr. Opin. Colloid Interface Sci."},{"key":"10.1016\/j.jconrel.2025.113682_bb0125","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1158\/1078-0432.CCR-09-2891","article-title":"Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway","volume":"16","author":"Zitvogel","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2025.113682_bb0130","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3390\/cells10010130","article-title":"Calreticulin\u2014multifunctional chaperone in immunogenic cell death: potential significance as a prognostic biomarker in ovarian cancer patients","volume":"10","author":"Kielbik","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jconrel.2025.113682_bb0135","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1158\/0008-5472.CAN-14-3098","article-title":"Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-kB to foster an immunosuppressive tumor microenvironment in ovarian cancer","volume":"75","author":"Peng","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2025.113682_bb0140","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1172\/JCI96113","article-title":"Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade\u2013mediated tumor regression","volume":"128","author":"Lin","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2025.113682_bb0145","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","article-title":"The untapped potential of ascites in ovarian cancer research and treatment","volume":"123","author":"Ford","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2025.113682_bb0150","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/cancers10080244","article-title":"Ovarian cancer immunotherapy: preclinical models and emerging therapeutics","volume":"10","author":"McCloskey","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2025.113682_bb0155","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-13-1550","article-title":"Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer","volume":"73","author":"Duraiswamy","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2025.113682_bb0160","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fonc.2013.00256","article-title":"Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research","volume":"3","author":"Ahmed","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2025.113682_bb0165","series-title":"Annual Meeting of the Controlled Release Society, Las Vegas, NV","article-title":"Nanomedicine strategies for heating cold tumors with concurrent PD-L1 attenuation","author":"Faruque","year":"2023"},{"key":"10.1016\/j.jconrel.2025.113682_bb0170","doi-asserted-by":"crossref","first-page":"18712","DOI":"10.1021\/acsnano.4c06183","article-title":"A self-cascade penetrating brain tumor immunotherapy mediated by near-infrared II cell membrane-disrupting nanoflakes via detained dendritic cells","volume":"18","author":"Yalamandala","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.113682_bb0175","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1021\/acsnano.4c09525","article-title":"Reprograming dysfunctional dendritic cells by a versatile catalytic dual oxide antigen-captured nanosponge for remotely enhancing lung metastasis immunotherapy","volume":"19","author":"Chiang","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.113682_bb0180","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202401783","article-title":"Nanomedicine in immunotherapy for non-small cell lung cancer: applications and perspectives","volume":"9","author":"Liao","year":"2025","journal-title":"Small Methods"},{"key":"10.1016\/j.jconrel.2025.113682_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105301","article-title":"Reprogramming the immunosuppressive tumor microenvironment through nanomedicine: an immunometabolism perspective","volume":"107","author":"Liu","year":"2024","journal-title":"eBioMedicine"},{"key":"10.1016\/j.jconrel.2025.113682_bb0190","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3389\/fonc.2018.00595","article-title":"Ascites volumes and the ovarian cancer microenvironment","volume":"8","author":"Penet","year":"2018","journal-title":"Front. Oncol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925003025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925003025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:02:01Z","timestamp":1777870921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925003025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":38,"alternative-id":["S0168365925003025"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113682","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-L1 targeted antibody-polymer-Epirubicin conjugate prolongs survival in a preclinical murine model of advanced ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113682","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113682"}}